These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 26558086)

  • 1. Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons.
    Ferguson JE; Carson CC
    Arab J Urol; 2013 Sep; 11(3):222-9. PubMed ID: 26558086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vardenafil improves penile erection in type 2 diabetes mellitus patients with erectile dysfunction: role of tropomyosin.
    Zamorano-León JJ; Olivier C; de Las Heras N; Mateos-Cáceres PJ; Brime Menéndez R; Rodríguez-Sierra P; Martín Palacios N; Manso LS; Modrego J; Segura A; Macaya C; López-Farré AJ
    J Sex Med; 2013 Dec; 10(12):3110-20. PubMed ID: 24112450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
    Cui Y; Liu X; Shi L; Gao Z
    Andrologia; 2016 Feb; 48(1):20-8. PubMed ID: 25684196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
    Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J
    J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
    Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
    Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New treatment options for erectile dysfunction in patients with diabetes mellitus.
    Basu A; Ryder RE
    Drugs; 2004; 64(23):2667-88. PubMed ID: 15537369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effects of BAY 60-4552 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure.
    Albersen M; Linsen L; Tinel H; Sandner P; Van Renterghem K
    J Sex Med; 2013 May; 10(5):1268-77. PubMed ID: 23421435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterases 5 Inhibitors and Erectile Dysfunction Recovery after Pelvic Surgery: Future Perspectives for New Drugs and New Formulations.
    Lombardo R; Tema G; De Nunzio C
    Curr Drug Targets; 2021; 22(1):31-37. PubMed ID: 32981502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction.
    Megas G; Papadopoulos G; Stathouros G; Moschonas D; Gkialas I; Ntoumas K
    BJU Int; 2013 Jul; 112(2):E169-76. PubMed ID: 23253640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy.
    Kim ED; Seftel AD; Goldfischer ER; Ni X; Burns PR
    J Sex Med; 2014 Mar; 11(3):820-30. PubMed ID: 23841532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current use of phosphodiesterase inhibitors in urology.
    Hakky TS; Jain L
    Turk J Urol; 2015 Jun; 41(2):88-92. PubMed ID: 26328208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
    Corbin JD; Francis SH; Webb DJ
    Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.
    Bruzziches R; Francomano D; Gareri P; Lenzi A; Aversa A
    Expert Opin Pharmacother; 2013 Jul; 14(10):1333-44. PubMed ID: 23675780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vardenafil: a review of its use in erectile dysfunction.
    Keating GM; Scott LJ
    Drugs; 2003; 63(23):2673-703. PubMed ID: 14636086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
    Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G
    J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avanafil for erectile dysfunction.
    Kyle JA; Brown DA; Hill JK
    Ann Pharmacother; 2013 Oct; 47(10):1312-20. PubMed ID: 24259695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
    Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
    J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on vardenafil in erectile dysfunction.
    Keating GM; Scott LJ
    Drugs Aging; 2004; 21(2):135-40. PubMed ID: 14960129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties.
    Kedia GT; Uckert S; Assadi-Pour F; Kuczyk MA; Albrecht K
    Ther Adv Urol; 2013 Feb; 5(1):35-41. PubMed ID: 23372609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.